1334674-88-2Relevant articles and documents
DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
-
Paragraph 0358, (2015/11/27)
The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Its use as an inhibitor and JAK and SYK deriv. pyrroropyrazine
-
Paragraph 0127; 0130, (2016/11/07)
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R2, R3, and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
3-amido pyrrolopyrazine JAK kinase inhibitors: Development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models
Soth, Michael,Hermann, Johannes C.,Yee, Calvin,Alam, Muzaffar,Barnett, Jim W.,Berry, Pamela,Browner, Michelle F.,Frank, Karl,Frauchiger, Sandra,Harris, Seth,He, Yang,Hekmat-Nejad, Mohammad,Hendricks, Than,Henningsen, Robert,Hilgenkamp, Ramona,Ho, Hoangdung,Hoffman, Ann,Hsu, Pei-Yuan,Hu, Dong-Qing,Itano, Andrea,Jaime-Figueroa, Saul,Jahangir, Alam,Jin, Sue,Kuglstatter, Andreas,Kutach, Alan K.,Liao, Cheng,Lynch, Stephen,Menke, John,Niu, Linghao,Patel, Vaishali,Railkar, Aruna,Roy, Douglas,Shao, Ada,Shaw, David,Steiner, Sandra,Sun, Yongliang,Tan, Seng-Lai,Wang, Sandra,Vu, Minh Diem
, p. 345 - 356 (2013/02/23)
The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cycl